# Profusa

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/profusa

- Industry: Medical Devices & Equipment
- Headquarters: Berkeley, US
- Website: www.profusa.com/
- Total disclosed funding: $58M
- Latest round: Series C (Aug 14, 2018)
- Investors on record: 7

## About

Founded in 2009 and based in San Francisco, US, Profusa, Inc. specializing in biosensor technology. and it is a biotechnology company focused on developing innovative tissue-integrating biosensors for continuous monitoring of body chemistries, primarily aimed at enhancing patient care through real-time health data. The company has undergone significant development with its latest product, the Lumee® Oxygen Platform. Profusa, Inc. specializes in the development of innovative tissue-integrating biosensors, particularly its flagship product, the Lumee® Oxygen Platform. This platform is designed for continuous monitoring of body chemistries, focusing on tracking oxygen levels and enabling insights into microvascular perfusion, addressing critical healthcare needs for patients with conditions like chronic limb-threatening ischemia. Profusa’s biosensors are engineered for long-term monitoring and cater to healthcare providers, research institutions, and telehealth services requiring advanced patient care solutions.Profusa’s revenue model is based on direct partnerships with healthcare providers and institutions, focusing on the deployment of its Lumee® Oxygen Platform. The company engages in B2B transactions, allowing hospitals and clinics to incorporate Profusa's technology into their patient care workflows. This likely involves subscription-based access to the biosensor data platform and partnerships for research and development initiatives, with pricing tailored to meet the healthcare market's needs. The company is focused on expanding its market presence and exploring new product developments. Specific geographical regions for expansion have yet to be detailed, but the continued innovation in its monitoring technologies indicates a strategic aim to enhance healthcare delivery on a larger scale.

## Funding rounds

- Series C, Aug 14, 2018, $45M — Atinum Investment, Maxim Ventures, Tasly Pharmaceutical Co., Ltd., VMS Asset Management, 3E Bioventures Capital
- Series B, Dec 16, 2015, $13M — Asset Management Ventures, Qihoo 360 Venture Capital, 3E Bioventures Capital

## Investors

- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series B
- Qihoo 360 Venture Capital (https://capitalatlas.ai/funds/qihoo-360-venture-capital) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B, Series C
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series C
- Maxim Ventures (https://capitalatlas.ai/funds/maxim-ventures) — Series C
- Tasly Pharmaceutical Co., Ltd. — Series C
- VMS Asset Management (https://capitalatlas.ai/funds/vms-asset-management) — Series C